These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11371997)

  • 21. A critical tipping point.
    Zuckerman MB
    US News World Rep; 2002 Apr; 132(13):72. PubMed ID: 11993366
    [No Abstract]   [Full Text] [Related]  

  • 22. [Does the public sector have an independent research role in the development of drugs?].
    Poulsen HE; Grønlykke TB
    Ugeskr Laeger; 2003 Apr; 165(16):1674-6. PubMed ID: 12756828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Development of new drugs is too expensive].
    Andreasen J
    Ugeskr Laeger; 2003 May; 165(19):1959-60. PubMed ID: 12795066
    [No Abstract]   [Full Text] [Related]  

  • 24. FDA: approval of generic drug reversed by U.S. Court of Appeals.
    Beliveau S
    J Law Med Ethics; 2002; 30(1):120-2. PubMed ID: 11905262
    [No Abstract]   [Full Text] [Related]  

  • 25. Extraordinary claims require extraordinary evidence.
    Light DW; Warburton RN
    J Health Econ; 2005 Sep; 24(5):1030-3; discussion 1034-53. PubMed ID: 16087260
    [No Abstract]   [Full Text] [Related]  

  • 26. Productivity counts--but the definition is key.
    Mervis J
    Science; 2005 Jul; 309(5735):726. PubMed ID: 16051784
    [No Abstract]   [Full Text] [Related]  

  • 27. Research and development costs for drugs.
    Riggs TL
    Lancet; 2004 Jan; 363(9404):184. PubMed ID: 14738789
    [No Abstract]   [Full Text] [Related]  

  • 28. The price of innovation: new estimates of drug development costs.
    DiMasi JA; Hansen RW; Grabowski HG
    J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are drugs from the jungle cheaper to develop?
    Randal J
    J Natl Cancer Inst; 1995 May; 87(10):715. PubMed ID: 7563148
    [No Abstract]   [Full Text] [Related]  

  • 30. Downward pressure on US drug prices if Kerry wins.
    Andrawiss M
    Drug Discov Today; 2004 Oct; 9(20):861. PubMed ID: 15475314
    [No Abstract]   [Full Text] [Related]  

  • 31. Investigational drug tracking: Phases I-III and NDA submissions--Part I.
    Grant KL
    Hosp Pharm; 1994 Sep; 29(9):830-6, 839-44, 847-52 passim. PubMed ID: 10137064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sources of regulatory information for pharmacists.
    Goldwire MA; Rumore MM
    Am J Hosp Pharm; 1993 Jun; 50(6):1175-81. PubMed ID: 8517457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Move by FDA will speed approval of drugs across Europe.
    Reynolds T
    J Natl Cancer Inst; 1996 Jan; 88(2):78. PubMed ID: 8537981
    [No Abstract]   [Full Text] [Related]  

  • 34. The role of exploratory investigational new drugs for translating radiopharmaceuticals into first-in-human studies.
    Schwarz SW; Oyama R
    J Nucl Med; 2015 Apr; 56(4):497-500. PubMed ID: 25766895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SEC going after insider trading based on medical research results. Securities Exchange Commission.
    Skolnick AA
    JAMA; 1998 Jul; 280(1):10-1. PubMed ID: 9660347
    [No Abstract]   [Full Text] [Related]  

  • 36. Economics of new oncology drug development.
    DiMasi JA; Grabowski HG
    J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Good drug, bad luck: business, regulatory issues can create obstacles for drug development.
    Goldman B
    J Natl Cancer Inst; 2004 Nov; 96(21):1573-4. PubMed ID: 15523084
    [No Abstract]   [Full Text] [Related]  

  • 38. THE FOOD AND DRUG ADMINISTRATION'S VIEW OF INVESTIGATIONAL DRUGS.
    MEYERS EL
    Am J Pharm Sci Support Public Health; 1963 Jun; 135():219-29. PubMed ID: 14046043
    [No Abstract]   [Full Text] [Related]  

  • 39. Approval of new drugs in the United States. Comparison with the United Kingdom, Germany, and Japan.
    Kessler DA; Hass AE; Feiden KL; Lumpkin M; Temple R
    JAMA; 1996 Dec; 276(22):1826-31. PubMed ID: 8946904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Food and Drug Administration perspective: use of an investigational drug in a medical emergency.
    Schultheis LW; Rappaport BA
    Anesth Analg; 2007 Mar; 104(3):479-80. PubMed ID: 17312189
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.